eLife (Apr 2020)

Rapamycin rejuvenates oral health in aging mice

  • Jonathan Y An,
  • Kristopher A Kerns,
  • Andrew Ouellette,
  • Laura Robinson,
  • H Douglas Morris,
  • Catherine Kaczorowski,
  • So-Il Park,
  • Title Mekvanich,
  • Alex Kang,
  • Jeffrey S McLean,
  • Timothy C Cox,
  • Matt Kaeberlein

DOI
https://doi.org/10.7554/eLife.54318
Journal volume & issue
Vol. 9

Abstract

Read online

Periodontal disease is an age-associated disorder clinically defined by periodontal bone loss, inflammation of the specialized tissues that surround and support the tooth, and microbiome dysbiosis. Currently, there is no therapy for reversing periodontal disease, and treatment is generally restricted to preventive measures or tooth extraction. The FDA-approved drug rapamycin slows aging and extends lifespan in multiple organisms, including mice. Here, we demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mice, including regeneration of periodontal bone, attenuation of gingival and periodontal bone inflammation, and revertive shift of the oral microbiome toward a more youthful composition. This provides a geroscience strategy to potentially rejuvenate oral health and reverse periodontal disease in the elderly.

Keywords